GSK's Barron joins hands with Doudna, Weissman to deploy CRISPR tech in drug discovery
When Hal Barron unveiled his grand plan to turn GlaxoSmithKline’s R&D group around, he championed genetics as one of two key focuses for the UK pharma giant, announcing a discovery deal with 23andme and pledging to focus more on CRISPR tech as well as machine learning. A year later, the R&D chief is building on that promise as he seals a new pact with two prominent CRISPR researchers in his neighborhood in San Francisco.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.